With mounting legal challenges to its hepatitis C patent estate abroad, and rising competition at home, California’s Gilead Sciences (Nasdaq: GILD) has decided to get ahead of the game and launch its own approved generics for Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir).
The decision to become its own copycat in HCV makes commercial sense, given the complexity of the US healthcare system, where the firm says discounts “may not always translate into lower costs for patients.”
By cutting out the middlemen, Gilead hopes it can maintain its end of a shrinking market opportunity. The firm expects sales of its HCV business to come in under $4 billion this year, less than half the figure from 2017 and a precipitous drop from the some $20 billion peak of 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze